TPA: How Fast is Fast?
What is the shortest time within which you have given a patient TPA?
How fast is fast when it comes to tissue plasminogen activator (TPA) administration?
TPA, given only to patients who meet certain inclusion criteria, may only be given within a few hours of stroke onset. Based on the timing criteria, TPA is not an option for many patients who either do not recognize that they are having a stroke or who do not seek medical attention within the short time window.
Ultrafast TPA administration
In the meantime, doctors and healthcare systems are researching ways to get TPA to patients faster. The idea of faster stroke evaluation and TPA administration has been part of an effort to streamline the process in emergency and stroke center settings. Some measures used to evaluate efficiency in stroke care and TPA use include door to computed tomography time (DTCT) and door to needle time (DTNT).
A
Another study, this one in Denmark, reported an
TPA administration time relative to patient outcome
Studies show that timely administration of TPA is associated with reduced morbidity and mortality. A
So far, there has not been as much study of outcomes of TPA administration within 30 minutes of arrival to the hospital. But the incremental improvements seen with faster treatment times suggests that ultrafast TPA administration may lead to better outcomes too.
Implementing stroke protocols to achieve short DTNT
The emphasis on shorter DTNT may have an impact on more hospitals as this goal becomes more realistic. The distribution of resources necessary to implement efficient stroke protocols cannot always be optimal among all health care centers. This is consistent with the idea that designated stroke centers are preferred destinations for stroke patients.
There are, of course, patients who cannot reach stroke centers within a short period. New approaches to quick assessment and treatment of these individuals include resources such as telemedicine to fill that gap.
Stroke treatment is improving, and current improvements are largely based on timeliness of assessment and treatment. As on-site advancements continue, methods of reaching patients who are not located near the most efficient stroke centers will likely continue as well.
References:
1. Hillen ME, He W, Al-Qudah Z, et al. Long-term impact of implementation of a stroke protocol on door-to-needle time in the administration of intravenous tissue plasminogen activator. J Stroke Cerebrovasc Dis. 201726(7):1569-1572.
2. Hansen CK, Christensen A, Rodgers H, et al. CT and MRI-based door-needle-times for acute stroke patients: a quasi-randomized clinical trial. Clin Neurol Neurosurg. 2017; 10;159:42-49.
3. Saver JL Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013; 309(23):2480-2488.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.